Home/Pipeline/DT-DEC01

DT-DEC01

Duchenne Muscular Dystrophy (DMD)

Phase 1Active (Dose Escalation)

Key Facts

Indication

Duchenne Muscular Dystrophy (DMD)

Phase

Phase 1

Status

Active (Dose Escalation)

Company

Dystrogen Therapeutics

About Dystrogen Therapeutics

Dystrogen Therapeutics is developing a first-in-class chimeric cell therapy platform with broad applications in genetic and degenerative disorders. Its core technology involves fusing donor and recipient cells to create 'Dystrophin Expressing Chimeric (DEC)' cells that evade immune rejection, eliminating the need for immunosuppression. The company is initially focused on Duchenne Muscular Dystrophy, with a Phase 1 trial underway, and has preclinical programs targeting sarcopenia, age-related muscle loss, and neurodegenerative diseases. Dystrogen's approach represents a potentially paradigm-shifting alternative to gene therapy and other advanced modalities.

View full company profile

Therapeutic Areas

Muscular Dystrophy Neuromuscular Diseases Rare Diseases Sarcopenia Neurodegenerative Diseases

Other Duchenne Muscular Dystrophy (DMD) Drugs

Drug	Company	Phase	Status
AOC Program	Avidity Biosciences	Clinical	Active
AGAMREE® (vamorolone)	Catalyst Pharmaceuticals	Approved/Commercial	Marketed; Long-term safety study (SUMMIT Registry) ongoing
SRP-9001 (delandistrogene moxeparvovec)	Sarepta Therapeutics	Approved	Commercial
Deramiocel (CAP-1002)	Capricor Therapeutics	Phase 3	BLA Submitted, PDUFA date established
RGX-202	REGENXBIO	Phase 1/2	Active
PBGENE-DMD	Precision BioSciences	Phase 1/2	Active - IND Cleared; Clinical trial initiation